$ICUI

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.

ICU MEDICAL INC/DE (ICUI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026er.htm EX-99.1 Document Exhibit 99.1 ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufa

ICU Medical (NASDAQ: ICUI) is set to report Q2 earnings Thursday after market close. The prior quarter revenue was $525.8 million, down 12.3% year over year, and it beat EPS estimates. For Q2, analysts expect revenue to decline about 2% year over year. The article cites an average analyst price target of $176.63 versus a $172 share price.

Analysts issued multiple rating and price-target changes across Wall Street. JPMorgan upgraded Openlane to overweight and raised its Dec 2026 PT to $38; UBS upgraded Ecolab to buy with a $325 PT; Barclays upgraded SanDisk to overweight. Micron’s PT was raised to $1,175 by Barclays. JPMorgan upgraded FedEx to overweight ahead of late-June earnings.

This article reports on an SEC Form 144 filing by ICU MEDICAL INC/DE (ICUI). The filing details a proposed sale of 2424 common shares with an aggregate market value of $297,933.84, acquired through the exercise of options under a registered plan. The purpose of the Form 144 is to provide notice of the proposed sale of securities under Rule 144 of the Securities Act of 1933.

ICU Medical (NASDAQ:ICUI) reported its Q1 2026 financial results, showing a 12% year-over-year revenue decline to $526 million due to the deconsolidation of its IV Solutions joint venture, but maintained 1% organic growth. The company exceeded earnings expectations with an adjusted EPS of $1.97 and saw strong performance in its Infusion Systems segment, while facing challenges from tariffs, logistics costs, and FDA review timelines. ICU Medical provided positive forward guidance for Q2 and Q3 2026, indicating expected sequential improvement.

Wall Street Zen downgraded ICU Medical (NASDAQ:ICUI) from "buy" to "hold." This comes after ICU Medical reported Q4 EPS of $1.91, exceeding estimates, but revenue of $535.9M missed expectations and was down 14.1% year-over-year. The medical instruments supplier has a mixed analyst outlook with an average rating of "Moderate Buy" and institutional ownership around 96%.

Purcell & Lefkowitz LLP has launched a shareholder investigation into ICU Medical, Inc. (NASDAQ: ICUI) to determine if the company's directors breached their fiduciary duties through recent corporate actions. Shareholders of ICU Medical are invited to contact the firm for more information regarding their rights and options. The law firm specializes in representing shareholders affected by securities fraud and corporate misconduct.

SAN CLEMENTE, Calif., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- ICU Medical, Inc. ( NASDAQ:ICUI ) , a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare ...